Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000724874 | SCV000228031 | uncertain significance | not provided | 2015-06-04 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000724874 | SCV000513071 | benign | not provided | 2020-01-10 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001084885 | SCV000651013 | benign | Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000724874 | SCV002545559 | likely benign | not provided | 2024-07-01 | criteria provided, single submitter | clinical testing | FLNC: BS1 |
Ambry Genetics | RCV002354450 | SCV002622342 | likely benign | Cardiovascular phenotype | 2019-01-09 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
CHEO Genetics Diagnostic Laboratory, |
RCV003150047 | SCV003837898 | benign | Cardiomyopathy | 2021-12-20 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001706129 | SCV004122458 | likely benign | not specified | 2023-10-31 | criteria provided, single submitter | clinical testing | Variant summary: FLNC c.4022G>A (p.Arg1341Gln) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.001 in 248756 control chromosomes in the gnomAD database, including 1 homozygotes. The observed variant frequency is approximately 133.79 fold of the estimated maximal expected allele frequency for a pathogenic variant in FLNC causing Dilated Cardiomyopathy phenotype (7.8e-06), strongly suggesting that the variant is benign. c.4022G>A has been reported in the literature in individuals affected with Dilated Cardiomyopathy, without strong evidence for causality. These report(s) do not provide unequivocal conclusions about association of the variant with Dilated Cardiomyopathy. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 28356264, 25208129). Six submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. One submitter classified the variant as VUS whle five classified the variant as likely benign/benign. Based on the evidence outlined above, the variant was classified as likely benign. |
Prevention |
RCV003907585 | SCV004727308 | benign | FLNC-related disorder | 2020-03-11 | criteria provided, single submitter | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Clinical Genetics, |
RCV001706129 | SCV001919732 | benign | not specified | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000724874 | SCV001929608 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000724874 | SCV001970442 | likely benign | not provided | no assertion criteria provided | clinical testing |